Changing Patterns of Drug Utilization in a Neonatal Intensive Care Population

ABSTRACT

Newborns in the neonatal intensive care unit (NICU) typically are exposed to a large number of drugs and are especially vulnerable to adverse drug reactions. It is important to review changes in drug use patterns periodically in the NICU to identify newly introduced drugs as well as drugs with increasing use. The objective of this study was to determine the changes in drug utilization patterns over a 7-year period in an NICU population. Drug utilization of 2332 neonates treated at an intramural NICU between January 1, 1997 and December 31, 1998, and 2691 neonates between January 1, 2001 and June 30, 2004 was analyzed using chi-square tests, t tests, and linear regression. There was an increased utilization of antibiotics, central nervous system drugs, endocrine agents, cardiovascular and gastrointestinal drugs, and a decreased utilization of ophthalmic drugs. No changes in nutritional, biological, renal, and pulmonary drugs were observed. Some individual drug changes include an increased use of vancomycin, cefepime, caffeine, and a decreased use of morphine. Significant changes in drug utilization patterns in an NICU were observed during a 7-year period. These data are useful in monitoring drug resistance patterns, adverse drug reactions, and prioritizing areas of relevant therapeutic research and educational programs.

KEYWORDS

Drug utilization - NICU - premature - neonate

REFERENCES

• 1 Bonati M. Epidemiologic evaluation of drug use in children.  J Clin Pharmacol. 1994;  34 300-305
• 2 Aranda J V, Cohen S, Neims A H. Drug utilization in a newborn intensive care unit.  J Pediatr. 1976;  89 315-317
• 3 Aranda J V, Collinge J M, Clarkson S. Epidemiologic aspects of drug utilization in a newborn intensive care unit.  Semin Perinatol. 1982;  6 148-154
• 4 Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate.  Semin Fetal Neonatal Med. 2005;  10 115-122
• 5 Daniell A J, Darlow B A. Audit of drug usage in a regional neonatal intensive care unit.  Aust Paediatr J. 1989;  25 207-210
• 6 Gortner L, Bernsau U, Brand M et al.. Drug utilization in very premature infants in neonatal intensive care units.  Dev Pharmacol Ther. 1991;  17 167-171
• 7 Early neonatal drug utilization in preterm newborns in neonatal intensive care units. Italian Collaborative Group on Preterm Delivery.  Dev Pharmacol Ther. 1988;  11 1-7
• 8 Lesko S M, Epstein M F, Mitchell A A. Recent patterns of drug use in newborn intensive care.  J Pediatr. 1990;  116 985-990
• 9 Aranda J V, Clarkson S, Collinge J M. Changing pattern of drug utilization in a neonatal intensive care unit.  Am J Perinatol. 1983;  1 28-30
• 10 Faix R G, Kovarik S M, Shaw T R, Johnson R V. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study.  Pediatrics. 1989;  83 101-107
• 11 Weese-Mayer D E, Fondriest D W, Brouillette R T, Shulman S T. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study.  Pediatr Infect Dis J. 1987;  6 190-196
• 12 Frattarelli D A, Reed M D, Giacoia G P, Aranda J V. Antifungals in systemic neonatal candidiasis.  Drugs. 2004;  64 949-968
• 13 Blumer J L, Reed M D, Knupp C. Review of the pharmacokinetics of cefepime in children.  Pediatr Infect Dis J. 2001;  20 337-342
• 14 Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate.  Antimicrob Agents Chemother. 2005;  49 2760-2766
• 15 Acolet D, Ahmet Z, Houang E, Hurley R, Kaufmann M E. Enterobacter cloacae in a neonatal intensive care unit: account of an outbreak and its relationship to use of third generation cephalosporins.  J Hosp Infect. 1994;  28 273-286
• 16 McDougal A, Ling E W, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates.  Ther Drug Monit. 1995;  17 319-326
• 17 Healy C M, Hulten K G, Palazzi D L, Campbell J R, Baker C J. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.  Clin Infect Dis. 2004;  39 1460-1466
• 18 Saiman L, Cronquist A, Wu F et al.. An outbreak of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.  Infect Control Hosp Epidemiol. 2003;  24 317-321
• 19 Committee on Fetus and Newborn . Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.  Pediatrics. 2002;  109 330-338
• 20 Shinwell E S, Karplus M, Reich D et al.. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F177-F181
• 21 Gannon B A. Theophylline or caffeine: which is best for apnea of prematurity?.  Neonatal Netw. 2000;  19 33-36
• 22 Steer P A, Henderson-Smart D J. Caffeine versus theophylline for apnea in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) CD000273
• 23 Anand K J, Hall R W, Desai N et al.. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial.  Lancet. 2004;  363 1673-1682
• 24 Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment.  J Pediatr Endocrinol Metab. 1999;  12 549-553
• 25 McKiernan P J. Neonatal cholestasis.  Semin Neonatol. 2002;  7 153-165
• 26 Van Marter L J. Strategies for preventing bronchopulmonary dysplasia.  Curr Opin Pediatr. 2005;  17 174-180
• 27 D'Angio C T, Maniscalco W M. Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.  Paediatr Drugs. 2004;  6 303-330
• 28 Kaushal R, Bates D W, Landrigan C et al.. Medication errors and adverse drug events in pediatric inpatients.  JAMA. 2001;  285 2114-2120